Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20200930xex32d2.htm |
| EX-31.2 - EXHIBIT 31.2 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20200930xex31d2.htm |
| EX-31.1 - EXHIBIT 31.1 - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20200930xex31d1.htm |
| 10-Q - FORM 10-Q - BRAINSTORM CELL THERAPEUTICS INC. | bcli-20200930x10q.htm |
EXHIBIT 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
In connection with the accompanying Quarterly Report on Form 10-Q of BrainStorm Cell Therapeutics Inc. for the period ended September 30, 2020, the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:
(1) the Quarterly Report on Form 10-Q for the period ended September 30, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Quarterly Report on Form 10-Q for the period ended September 30, 2020 fairly presents, in all material respects, the financial condition and results of operations.
October 15, 2020 |
| /s/ Chaim Lebovits |
| | Name: Chaim Lebovits |
| | Title: Chief Executive Officer |
| | (Principal Executive Officer) |
The foregoing certification is not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and is not to be incorporated by reference into any filing of BrainStorm Cell Therapeutics Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.